Blocking mitochondrial fission helped immunotherapy build longer-lived T cells — in a lung cancer mouse model

Edited by Samael A. Tejada, Founder & Editor-in-Chief

The idea underneath is sound and increasingly supported: a T cell's mitochondria shape how long it can keep fighting, and fused, elongated networks are the signature of memory cells that persist. What this study adds is a drug-combination result in a lung model. What it cannot yet add is certainty about which of Mdivi-1's targets did the work, or any evidence in a person.

What did the combination do in the model?

In the preclinical lung cancer model, anti-PD-1 treatment combined with Mdivi-1 produced a stronger antitumor effect than checkpoint blockade alone, and the T cells involved shifted toward a memory-like phenotype — the state in which CD8 T cells persist, self-renew and respond again on re-challenge, rather than burning out into exhaustion. The mechanistic story the authors build on is mitochondrial shape: DRP1-driven fission fragments T-cell mitochondria during effector responses, while memory cells carry fused networks with spare respiratory capacity. Blocking fission pharmacologically tilted the cells toward the memory configuration.

Why is Mdivi-1's attribution problem important here?

Mdivi-1 was introduced in 2008 as a selective DRP1 inhibitor, but a widely cited 2017 analysis showed it also reversibly inhibits mitochondrial complex I and alters reactive oxygen species independently of DRP1. That does not make this study's result wrong — the combination still outperformed anti-PD-1 alone in the model — but it changes what the result proves. If the benefit flows from complex I modulation rather than fission blockade, the drug-development path (and the safety questions) look different. The rigorous next step is genetic: reproduce the memory phenotype with DRP1-specific manipulation and show the drug adds nothing on top.

How far is this from a patient?

Several full steps. Mdivi-1 itself is a research compound, not a clinical drug candidate with human dosing and safety data; systemic fission blockade would also touch every healthy tissue that relies on mitochondrial division, from neurons to muscle. The realistic translation is narrower: ex-vivo conditioning of T cells for adoptive cell therapy, or a future fission modulator with cleaner selectivity tested first for safety. Until one of those produces human data, this story's correct label is a promising mouse result with an open mechanism question.

Where the evidence stands

• Established: Memory CD8 T cells carry fused mitochondrial networks and spare respiratory capacity compared with exhausted effector cells; Mdivi-1 inhibits DRP1-mediated fission and, independently, mitochondrial complex I (established in the methods literature since 2017).
• Preliminary: In a preclinical lung cancer model (OncoImmunology, Oct 27, 2026; DOI 10.1080/2162402X.2026.2615788), Mdivi-1 combined with anti-PD-1 promoted a memory-like T-cell phenotype and enhanced antitumor effect over checkpoint blockade alone.
• Absent: Human data of any kind, a DRP1-selective clinical compound, and proof that the benefit is caused by fission blockade rather than complex I inhibition.